EBR Systems to Host Investor Webinar on Q3 2026 Results on 10 November

Mukul

10 November 2026 12:56 PM AEDT

EBR Systems to Host Investor Webinar on Q3 2026 Results on 10 November

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

EBR Systems, Inc. (ASX:EBR), developer of a wireless cardiac pacing device for heart failure, has disclosed that its senior management team will host an investor webinar on Tuesday, 10 November 2026, to discuss the company's Q3 2026 results.

Key Points

EBR Systems will host an investor webinar on Tuesday, 10 November 2026, at 12:00pm AEDT (Monday, 9 November at 5:00pm PST)
The webinar is specifically linked to the company's Q3 2026 results release
EBR's senior management team will present and discuss the results
The company is described as the developer of the world's only wireless cardiac pacing device for heart failure

Investor Webinar Details for Q3 2026 Results

EBR Systems disclosed on 10 November 2026 that its senior management team will host an investor webinar to discuss the company's Q3 2026 results. The webinar is scheduled for Tuesday, 10 November 2026, at 12:00pm Australian Eastern Daylight Time, which corresponds to Monday, 9 November 2026, at 5:00pm Pacific Standard Time. The filing states that investors can register for the webinar via a provided link, and that a confirmation email containing information about joining the webinar will be sent following registration. The announcement was authorised for release by the EBR Systems Routine Disclosure Committee, a committee of the Board of Directors.

EBR Systems' WiSE Cardiac Technology

According to the filing, EBR Systems is a Silicon Valley-based company dedicated to treatment of cardiac rhythm disease through wireless cardiac pacing. The company's patented Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads. The filing describes WiSE technology as the world's only wireless, endocardial pacing system in clinical use for stimulating the heart's left ventricle. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). The filing states WiSE is an investigational device in most markets and is currently only available for sale in the US.

CDI Structure and Foreign Ownership Restrictions

The filing discloses that EBR's ASX-traded securities are Chess Depositary Interests (CDIs), issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 for offers or sales made outside the US. According to the filing, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any US state or other jurisdiction. The filing states that holders of EBR's CDIs are unable to sell the CDIs into the US or to a US person unless the resale of the CDIs is registered under the Securities Act or an exemption is available.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.